Tech Company Financing Transactions
Terns Pharmaceuticals Funding Round
Terns Pharmaceuticals secured a $80 million Series B funding round on 10/31/2018. Investors included OrbiMed, Vivo Capital and Decheng Capital.
Transaction Overview
Company Name
Announced On
10/31/2018
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series B
Investors
OrbiMed (Lead Investor) (Carl Gordon)
Vivo Capital (Lead Investor) (Shan Fu)
Proceeds Purpose
Proceeds to Support Development of Clinical and Preclinical NASH Candidates
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1065 East Hillsdale Blvd. 100
Foster City, CA 94404
USA
Foster City, CA 94404
USA
Phone
Website
Email Address
Overview
Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Senthil Sundaram
Chief Financial Officer
Mark Vignola
Chief Medical Officer
Erin Quirk
Chief Operating Officer
Bryan Yoon
Chief Scientific Officer
Weidong Zhong
Browse more venture capital transactions:
Prev: 10/31/2018: Imbed Biosciences venture capital transaction
Next: 10/31/2018: Coinbase venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs